

## **Solos Endoscopy, Inc. Appoints New Chief Financial Officer**

WESTPORT, January 15, 2015 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) a provider of quality medical devices to hospitals and clinics across the country, has announced that the company has appointed Mr. Claus Madsen as its new Chief Financial Officer.

The company's Chief Executive Officer, Dom Gatto stated, "we are pleased to have someone with Claus' background and experience to help restructure our capitalization and guide the company forward on a strong financial and accounting platform".

Mr. Madsen's career in finance and accounting began at Arthur Andersen & Co. He earned his CPA certification and reached the level of Senior Manager. While there, Mr. Madsen worked within the real estate, construction, leasing, banking and health care industries.

Upon departure from Arthur Andersen & Co., he joined the global investment and advisory firm Babcock and Brown Inc. As its Corporate Controller, he gained valuable experience in the day-to-day operation and administrative functions of a large multi-national operation. These included budget and cost controls, as well as board reporting and presentations.

Mr. Madsen was then recruited as the Chief Financial Officer at Acueity, Inc., a start-up medical device company focused on breast cancer diagnostics. As a primary adviser to the Chief Executive Officer, he prepared detailed business plans and presented to Venture Capitalist and other potential investment groups. His responsibilities included internal and external reporting, taxation, human resources, information technology and risk management. Mr. Madsen has recently been an interim Chief Financial Officer and financial consultant.

### **About Solos Endoscopy, Inc.:**

Solos Endoscopy Inc. has long provided quality healthcare instruments to Hospitals across the United States. For more than 30 Years, from medical schools to hospitals, surgeons have relied on Solos Endoscopy to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its line of products is available on the Company's website at: [www.solosendoscopy.com](http://www.solosendoscopy.com).

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding the potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at [www.otcm Markets.com](http://www.otcm Markets.com)). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Solos Endoscopy, Inc.  
Investor Relations  
(617) 360-9700